Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
- Japan to Participate in Global PIII Study of Forxiga for Type 1 Diabetes: AZ
August 25, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- Eli Lilly Files for Psoriasis Treatment Ixekizumab in Japan
August 24, 2015
- Janssen, National Center of Neurology and Psychiatry to Jointly Develop Biomarkers for AD Drug Reminyl
August 24, 2015
- EMA Accepts Application for Once-Weekly Oral Proteasome Inhibitor Ixazomib: Takeda
August 24, 2015
- Lilly Challenges Invalidation Ruling on Evista Usage Patent
August 21, 2015
- Astellas to Adopt One-Rep-for-One-Institution Regime in October
August 21, 2015
- Loxonin Suffers Most in Decrease in No. of Prescriptions Following Introduction of Generic Coefficient: Survey
August 21, 2015
- Announcement: 2015 Asia Pacific Meetings of ISMPP (Beijing on Aug. 30, Tokyo on Sept. 2)
August 20, 2015
- Anti-PD-L1 Antibody Atezolizumab Demonstrates Tumor Reduction Efficacy in NSCLC in PII Study: Roche
August 20, 2015
- Rheumatism Specialty Firm Ayumi Eyes Sales of 40-60 Billion Yen in 10 Years
August 19, 2015
- Shionogi Files Patent Suit over MSD’s HIV Drug
August 19, 2015
- Sawai’s Evista Generic Approved after Patent Battle
August 18, 2015
- Gene Techno Science, Mochida Tie Up for Joint Development of Biosimilars
August 18, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…